Center for Pharmacoeconomic Research

College of Pharmacy

Recent Publications

Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, Smith RA. Asthma outcomes: Healthcare utilization and costs. Journal of Allergy and Clinical Immunology. 2012;129(3 Suppl):S49-S64.

Cavallari LH, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-Michaels K, Viana MA, Shapiro NL, Nutescu EA. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenetics and Genomics. 2012;22(2):152-8.

Cavallari LH, Schumock GT. Cost is not a barrier to implementing clopidogrel pharmacogenetics. Pharmacotherapy. 2012;32(4):299-303.

Dabbous F, Kothari S, Pickard AS. Survey of the use of ISPOR resources by Chicago Regional Chapter members. ISPOR Connections. 2012;18(3):10-12.

DiDomenico RJ. Chapter 6. Fibrinolytics. In: Wiggins B, Sanoski S, eds. Emergency Cardiovascular Pharmacotherapy: A Point-of-Care Guide. Bethesda: American Society of Health-System Pharmacists. 2012.

Dolor RJ, Masica AL, Touchette DR, Smith SR, Schumock GT. Patient safety–focused medication therapy management: challenges affecting future implementation. American Journal of Managed Care. 2012;18(7):e238-e244.

Gerber BS, Rapacki L, Castillo A, Tilton J, Touchette DR, Mihailescu D, Berbaum M, Sharp L. Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with diabetes. BMC Public Health. 2012;12(1):891. [Epub ahead of print]

Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, Shah ND, Vermeulen LC, Schumock GT. Projecting future drug expenditures – 2012. American Journal of Health-System Pharmacy. 2012;69(5):405-21.

Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research. 2012. [Epub ahead of print].

Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, Nourjah P, Sauer B, Schumock GT, Sedrakyan A, Stürmer T, West SL, Schneeweiss S. The incident user design in comparative effectiveness research. Effective Health Care Program Research Report No. 32. AHRQ Publication No. 11(12)-EHC054-EF. Rockville, MD: Agency for Healthcare Research. 2012.

Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, Rodby RA, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Kosinsky M, Merrill JT, Weisman MH, Wallace DJ. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 2012;42(1):56-65.

Kirley K, Qato DM, Kornfield R, Stafford R, Alexander CG. National trends in oral anticoagulant use in the United States, 2007-2011. Circulation: Cardiovascular Quality and Outcomes. 2012;5(2):615-621.

Lamers L, Gudex C, Pickard AS, Rabin R, on behalf of the EuroQol Group. Improving EQ-5D instruments and exploring new valuation techniques. ISPOR Connections. 2012;18(1):10-11.

Lau DT, Stubbings JA. Medicare Part D research and policy highlights, 2012: Impact and insights. Clinical Therapeutics. 2012;34(4);904-914.

Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. Journal of Managed Care Pharmacy. 2012;18(5):363-74.

Lin FJ, Lee TA, Wong PS, Pickard AS. Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. Journal of Evaluation in Clinical Practice. 2012.

Lin FJ, Longworth L, Pickard AS. Evaluation of content on EQ-5D as compared to disease-specific utility measures. Quality of Life Research. 2012. [Epub ahead of print]

Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clinical Pharmacology and Therapeutics. 2012;91(4):660-5.

Mularski RA, McBurnie MA, Lindenauer PK, Lee TA, Vollmer WM, Au DH, Carson SS, Krishnan JA. Comparative effectiveness research in chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research. 2012; 1(1): 71-82.

Neufeld EJ, Recht M, Sabio H, Saxena K, Solem CT, Pickard AS, Gut RZ, Cooper DL. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value in Health. 2012;15(6):916-25.

Nutescu EA. Apixaban: a novel oral inhibitor of factor Xa. American Journal of Health-System Pharmacy. 2012;69(13):1113-26.

Patterson BW, Khare R*, Courtney M, Lee TA, Kyriacou DN. Cost-effectiveness of influenza vaccination of older adults in the emergency department setting. American Journal of Emergency Medicine. 2012; 30(7): 1072-1079.

Pickard AS, Ray S, Ganguli A, Cella D. Comparison of FACT- and EQ-5D-based utility scores in cancer. Value in Health. 2012;15(2):305-11.

Pickard AS, Tawk R, Shaw JW. The effect of chronic conditions on stated preferences for health. European Journal of Health Economics. 2012. [Epub ahead of print]

Qato DM, Alexander GC. Just because it’s low cost doesn’t mean it’s accessible. Journal of General Internal Medicine. 2012;27(10):1233-4.

Reardon G, Pandya N, Nutescu EA, Lamori J, Damaraju CV, Schein J, Bookhart BK. Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home. American Journal of Geriatric Pharmacotherapy. 2012;10(6):361-72.

Samp JC, Schumock GT, Pickard AS. Retracted publications in the drug literature. Pharmacotherapy. 2012;32(7):586-95.

Santayana EM, Grim SA, Janda WM, Layden JE, Lee TA, Clark NM. Risk factors and outcomes associated with vancomycin-resistant Enterococcus (VRE) infections with reduced susceptibility to linezolid. Diagnostic Microbiology and Infectious Disease. 2012; 74(1): 39-42

Schiff GD, Galanter WL, Duhig J, Koronkowski MJ, Lodolce AE, Pontikes P, Busker J, Touchette D, Walton S, Lambert BL. A prescription for improving drug formulary decision making. PLoS Medicine. 2012;9(5):1-7.

Schumock GT, Gibbons RA, Lee TA, Joo MJ, Stayner LT, Valuck RJ. The association between leukotriene-modifying agents and spontaneously reported suicide. Drug Information Journal. 2012;46(1): 99-106.

Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: A nested case-control study. Journal of Allergy and Clinical Immunology. 2012;130(2):368-375.

Schumock GT, Wong G, Stubbings J. Business Planning for Pharmacy Programs. In: Desselle S, Zagarrick D, eds. Second Edition. Pharmacy Management: Essentials for All Practice Settings. 3rd edition. New York: McGraw Hill Companies Inc. 2012.

Schumock GT, Wong G, Stubbings J. Strategic Planning in Pharmacy Organizations. In: Desselle S, Zagarrick D, eds. Second Edition. Pharmacy Management: Essentials for All Practice Settings. 3rd edition. New York: McGraw Hill Companies Inc. 2012.

Solem CT, Lee TA, Joo MJ, Lambert BL, Walton SM, Pickard AS. Complexity of medication use in newly diagnosed chronic obstructive pulmonary disease patients. American Journal of Geriatric Pharmacotherapy. 2012;10(2):110-122.

Stein BD, Bautista A, Schumock GT, Lee TA, Charbeneau JT, Lauderdale DS, Naureckas ET, Meltzer DO, Krishnan JA. The validity of ICD-9-CM diagnosis codes for identifying patients hospitalized for COPD exacerbations. Chest. 2012;141(1):87-93.

Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM, Hynes DM. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in cancer patients following FDA policy change. Pharmacotherapy. 2012; 32(11): 988-997.

Stubbings JA, Kliethermes MA, and Wagner M. Justifying and planning patient care services. In Chisolm-Burns M, Vaillancourt A, and Shepart M, eds, Pharmacy Management, Leadership, Marketing, and Finance. Second Edition. Burlington VT: Jones & Bartlett Learning. 2012;178-98.

Tarlov E, Lee TA, Weichle TW, Durazo-Arvizu R, Zhang Q, Perrin R, Bentrem D, Hynes DM. Reduced overall and event-free survival among colon cancer patients using dual system care. Cancer Epidemiology, Biomarkers & Prevention. 2012; 21(12): 2231-2241.

Tarlov E, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM, Hynes DM. Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. Supportive Care in Cancer. 2012; 20(8): 1649-1657.

Touchette DR, Masica AL, Dolor RJ, Schumock GT, Choi YK, Kim Y, Smith SR. The medication evaluation and drug use problem identification to improve safety in high risk Medicare beneficiaries (MEDIS-MB) study: Main results. Journal of the American Pharmaceutical Association. 2012;52:603-612.

Touchette DR, Rao S, Dhru P, Zhao W, Choi Y-K, Bhandari I, Stettin GD. Identification of and intervention to address therapeutic gaps in care in community pharmacies: The Illinois Project. American Journal of Managed Care. 2012;18(10):e364-e371.

Touchette DR, Stubbings J, Schumock G. Improving Medication Safety in High Risk Medicare Beneficiaries Toolkit. Effective Healthcare Research Report No. 38. AHRQ Publication No. 12-EHC027-EF. Rockville, MD: Agency for Healthcare Research and Quality. 2012.

Touchette DR, Yang Y, Tyriaki F, Galanter W. Economic analysis of alvimopan for prevention and management of post-operative ileus. Pharmacotherapy. 2012;32(2):120-128.

Tsai HH, Lin HW, Pickard AS, Tsai HY, Mahady GB. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. International Journal of Clinical Practice. 2012;66(11):1056-1078.

van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. Value in Health. 2012;15(5):708-15.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty. Journal of Medical Economics. 2012;15(4):644-53.

Young G, Solem CT, Hoffman K, Kabawat J, Pickard AS, Gut RZ, Cooper DL. Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). Journal of Blood Medicine. 2012;3:131-8.